News

The company enrolled the first patients in the study of BI 1482694 (HM61713) in patients with non-small cell lung cancer (NSCLC) whose tumours test positive for the T790M

The approval is subject to Mylan’s divestiture of several products after the consummation of the offer. Mylan is offering $75 in cash and 2.3 ordinary shares for each

The companies have started a phase I clinical trial to evaluate GSK’s investigational GSK3174998 as monotherapy in combination with Merck’s Keytruda (pembrolizumab) in patients with tumors that have

The acquisition was completed by means of a short-form merger under the Delaware law. Post the short-form merger, InSite Vision has become an indirect wholly-owned subsidiary of Sun

The companies will develop joint protocols that explore potential synergistic effects of their respective drug candidates, as well as potential new drug candidate opportunities. "After recent discussions with

The Conception Kit at-home system contains a comprehensive collection of materials including 24 ovulation predictors, three pregnancy tests, and the innovative Conception Cap. Patients who purchased the same

The existing partnership is in the field of chronic obstructive pulmonary disease (COPD). Under the extended deal, the parties will set up a second team of scientists from

In Switzerland, the classification of "transplant products" includes cell therapies such as Apligraf. With marketing approval of Apligraf, Switzerland has become the first country in Europe to grant

TruSkin has been developed to provide healthcare professionals a new option for treating large, chronic wounds in the Hospital Outpatient, Private Office, and/or Surgical Settings, where allograft options